New York healthtech investors backing digital health and medtech in 2026

New York closed $4.7B in healthtech deals across 240+ companies in 2025. Digital health took 48% of total funding. The city has more hospital systems and payer expertise than SF. You'll need clinical validation before anyone writes checks.

Quick list

Why New York for healthtech fundraising

New York has 45+ active healthtech-focused funds. Average seed round is $5.2M. Series A runs $15-25M. Series B hits $40-80M. That's 30% higher than SF for digital health but comparable for biotech.

The city has every major hospital system within 20 miles. NYU Langone, Mount Sinai, NewYork-Presbyterian, Northwell. If you're building clinical tools, you'll run pilots in Manhattan. Investors expect this and won't fund healthcare software without hospital partnerships.

New York investors understand payer economics better than anyone. They know CMS reimbursement codes, value-based care contracts, and Medicare Advantage. The "we'll figure out reimbursement later" pitch dies immediately. Show your revenue model or don't pitch.

Competition is less brutal than consumer but more technical than SaaS. You're pitching against companies with FDA clearances or published clinical studies. The bar is clinical evidence, not just revenue growth. Most funds see 1,200+ healthtech decks per year and invest in 2-4.

Late-stage capital exists but requires outcomes data. Oak HC/FT and General Catalyst write $50-150M checks, but only after you've proven clinical efficacy. Plan 18-24 months of pilots before Series B.

Picking the right New York healthtech investor

Local presence: Manhattan-based investors can intro you to chief medical officers at Mount Sinai or innovation leads at NYU Langone. These relationships cut pilot timelines from 12 months to 4 months. Remote investors can't navigate hospital procurement processes. NYC healthtech VCs know which health system executives actually make buying decisions vs who just attend innovation meetings.

Portfolio companies: Check if they've backed clinical tools vs consumer health vs healthcare infrastructure. Some funds only do B2B software for providers. Others won't touch anything requiring FDA approval. Review their last 12 deals, not their marketing site. If every portfolio company is a pharmacy benefits manager or claims platform, your mental health app won't fit their thesis.

Check sizes: Seed rounds run $4-7M. Series A is $15-25M. Series B hits $40-80M. New York healthtech investors write larger checks than general SaaS funds because clinical validation costs more. About 50% of NYC healthcare funds can lead rounds over $20M. Know who has deep pockets for clinical trials vs who taps out at Series A.

Local network: New York investors connect you to health system innovation teams, CMS regulatory experts, or hospital CFOs who control budgets. They'll intro you to Cigna, Aetna, or UnitedHealthcare if your model affects medical spend. Share your deck through Ellty trackable links. You'll see which clinical evidence slides get reviewed vs which business model sections get skipped.

Follow-on capacity: Most NYC healthtech funds have $150-500M under management. They'll fund seed through Series B, then need crossover investors like Fidelity or T. Rowe Price for growth rounds. Ask about follow-on reserves upfront. Healthcare companies need more capital than SaaS because clinical validation burns cash without generating revenue. Lead capture tools help NYC founders prove that content interest actually converts into real investor conversations or customer demand.

How to find and approach New York healthtech investors

Research local deals: Follow HLTH conference announcements and Rock Health's quarterly reports. They track 85% of meaningful digital health rounds. MedCity News covers hospital partnerships that signal investor interest. Fierce Healthcare reports on regulatory approvals that often precede funding rounds. Password-protecting PPT files is still one of the simplest ways founders can control who actually views their materials in New York’s fast-moving ecosystem.

Leverage local ecosystem: StartUp Health and Blueprint Health run healthtech accelerators in Manhattan. NYU Langone Innovation Center and Mount Sinai's BioDesign program connect founders to clinical partners. Join HealthTech Capital's founder network. These programs have direct pipelines to Oak HC/FT, Thrive, and General Catalyst.

Build relationships first: New York healthtech investors want clinical pilots before first meetings. Don't pitch with just a prototype. Get 2-3 hospital systems testing your product or published pilot results. The market expects clinical validation. Schedule intro calls after you have hospital MOUs signed.

Share your pitch deck: Upload to Ellty and create unique links for each fund. You'll see which investors spend time on your clinical outcomes data vs your revenue projections. NYC healthcare VCs care more about patient outcomes and reimbursement strategy than West Coast investors who focus on user growth. Track who's reviewing regulatory pathway vs who's skipping to team credentials.

Attend local events: HLTH in October and Health 2.0 in September pull every healthcare investor to major cities. JP Morgan Healthcare Conference in January is where late-stage deals happen. Digital Health NYC meetups happen monthly in Manhattan with 300+ attendees. That's where Rock Health and Oak HC/FT scout new companies.

Connect with portfolio founders: Message CEOs from your target fund's last 8 investments. Ask about clinical diligence requirements and decision timelines. Most respond within a week. New York healthtech founders are helpful because they know how hard hospital sales are and want the ecosystem to succeed.

Organize due diligence: Set up an Ellty data room before first meetings. Include your clinical study results, FDA regulatory strategy, reimbursement analysis, and hospital partnership agreements. New York healthtech investors will ask for IRB approvals, patient outcome data, and health economics models in first conversations. Have this ready or you'll lose 3 months gathering documents.

Understand local pace: Healthcare rounds close slower than SaaS in NYC. Twelve weeks from first meeting to term sheet is normal even with strong clinical data. You'll present to clinical advisors and healthcare operators in addition to investment partners. Budget 5-6 months start to finish. Investors need time for clinical diligence that doesn't exist in other sectors.

New York-specific considerations

New York healthtech investors require hospital partnerships before Series A. Seed rounds can close with pilot commitments, but Series A needs signed contracts with 3-5 health systems. That's stricter than SF where Letters of Intent work. Prove hospital buyers will actually pay.

Most NYC healthcare funds prefer B2B models over direct-to-consumer. If you're building consumer health apps without employer or payer contracts, expect skepticism. Enterprise motion with health system or insurance company revenue gets funded faster. Mental health and chronic disease management are exceptions where DTC works.

Expect deeper clinical diligence than other markets. New York investors have MDs and former hospital executives on staff. They'll review your clinical protocols, patient safety measures, and outcomes methodology. Budget 6-8 weeks for clinical review even after business terms are agreed. This doesn't happen in SF enterprise software deals.

18 top healthtech investors in New York

1. Oak HC/FT

They manage $4B focused exclusively on healthcare and fintech with best track record in value-based care.

• Recent Deals: Devoted Health ($300M Series C, 2019), Aledade ($123M Series D, 2020), Bright Health ($200M Series C, 2018), Clover Health ($130M Series C, 2017), Olive ($225M Series G, 2021)
• LinkedIn: Annie Lamont
• Sector Focus: Value-based care, healthcare IT, digital health, payer platforms, care delivery
• Stage Focus: Series A, Series B, Series C, Growth
• Office Location: 1 Canterbury Green, Stamford, CT (covers NYC market)
• Website: oakhcft.com

2. Thrive Capital

They backed Oscar Health early and invest $10-50M in healthcare technology at growth stages.

• Recent Deals: Oscar Health ($30M Series A, 2013), Zocdoc ($50M Series D, 2015), Capsule ($200M Series D, 2021), Cedar ($102M Series C, 2020), Cityblock Health ($65M Series B, 2019)
• LinkedIn: Joshua Kushner
• Sector Focus: Health insurance tech, digital pharmacy, care navigation, patient engagement, healthcare IT
• Stage Focus: Series A, Series B, Series C, Growth
• Office Location: 170 Fifth Avenue, Manhattan
• Website: thrivecap.com

3. .406 Ventures

They invest $2-15M in healthcare IT and digital health with strong east coast hospital network.

• Recent Deals: Zocdoc ($15M Series B, 2011), Buoy Health ($6.7M Series A, 2018), Definitive Healthcare ($20M growth, 2019), Kyruus ($8M Series B, 2014), HealthReveal ($4M Series A, 2014)
• LinkedIn: Maria Cirino
• Sector Focus: Healthcare IT, care navigation, provider data, patient access, clinical decision support
• Stage Focus: Series A, Series B, Growth
• Office Location: 50 Milk Street, Boston (active NYC office)
• Website: 406ventures.com

4. FirstMark Capital

They backed Flatiron Health early and invest across healthtech with enterprise software lens.

• Recent Deals: Flatiron Health ($20M Series B, 2014, sold to Roche for $1.9B), Zocdoc ($15M Series B, 2011), Oscar Health ($30M Series A, 2013), Quartet Health ($40M Series C, 2018), Spring Health ($76M Series C, 2021)
• LinkedIn: Rick Heitzmann
• Sector Focus: Healthcare data platforms, oncology tech, behavioral health, care coordination, clinical software
• Stage Focus: Series A, Series B, Series C
• Office Location: 100 Fifth Avenue, Manhattan
• Website: firstmarkcap.com

5. Insight Partners

They invest $20-100M in growth-stage healthcare software and health IT platforms.

• Recent Deals: Vericel ($45M growth, 2014), Definitive Healthcare ($88M growth, 2019), Veeva Systems ($7M Series A, 2007, IPO $400M), Modernizing Medicine ($231M growth, 2018), AdvancedMD ($75M growth, 2018)
• LinkedIn: Jeff Horing
• Sector Focus: Healthcare SaaS, health IT, EHR systems, practice management, life sciences software
• Stage Focus: Series B, Series C, Growth
• Office Location: 1114 Avenue of the Americas, Manhattan
• Website: insightpartners.com

6. Two Sigma Ventures

They invest $5-25M in data-driven healthcare companies with quantitative focus.

• Recent Deals: Flatiron Health ($20M Series B, 2014), Komodo Health ($50M Series C, 2020), Tempus ($70M Series E, 2019), Health Catalyst ($70M Series E, 2017), Livongo ($52.5M Series D, 2017)
• LinkedIn: Villi Iltchev
• Sector Focus: Healthcare data analytics, precision medicine, real-world evidence, clinical data platforms, AI diagnostics
• Stage Focus: Series A, Series B, Series C
• Office Location: 100 Avenue of the Americas, Manhattan
• Website: twosigmaventures.com

7. Primary Venture Partners

They invest in healthcare infrastructure and social determinants of health platforms.

• Recent Deals: Healthify ($8M Series A, 2017), Unite Us ($17M Series B, 2019), Cedar ($13M Series A, 2017), Quartet Health ($40M Series C, 2018), Eligible ($3.2M Series A, 2014)
• LinkedIn: Ben Sun
• Sector Focus: Social determinants of health, healthcare infrastructure, patient billing, care coordination, health equity
• Stage Focus: Series A, Series B
• Office Location: 55 Broadway, Manhattan
• Website: primaryvc.com

8. Lux Capital

They invest in frontier tech including CRISPR diagnostics and synthetic biology with $2-20M checks.

• Recent Deals: Mammoth Biosciences ($23M Series A, 2018), Ginkgo Bioworks ($45M Series C, 2016), Resilience ($800M Series B, 2021), 23andMe ($5M Series A, 2007), Desktop Metal ($14M Series A, 2015)
• LinkedIn: Josh Wolfe
• Sector Focus: CRISPR diagnostics, synthetic biology, biotech platforms, precision medicine, medical devices
• Stage Focus: Seed, Series A, Series B, Series C
• Office Location: 140 Broadway, Manhattan
• Website: luxcapital.com

9. RRE Ventures

They backed Zocdoc early and invest $3-10M in digital health and healthcare IT.

• Recent Deals: Zocdoc ($5M Series A, 2009), Quartet Health ($40M Series C, 2018), Folica ($3M Series A, 2010), MD Insider ($6M Series A, 2014), CareCloud ($3M Series A, 2009)
• LinkedIn: Stuart Ellman
• Sector Focus: Patient access, behavioral health integration, healthcare scheduling, practice management, telehealth
• Stage Focus: Seed, Series A, Series B
• Office Location: 130 East 59th Street, Manhattan
• Website: rre.com

10. General Catalyst

They led Livongo early and invest $5-50M across digital health and care delivery models.

• Recent Deals: Livongo ($8M Series A, 2014, exited at $18.5B to Teladoc), Oscar Health ($30M Series A, 2013), Snap Health ($26M Series A, 2021), Bright Health ($200M Series C, 2018), Devoted Health ($300M Series C, 2019)
• LinkedIn: Hemant Taneja
• Sector Focus: Chronic disease management, value-based care, health insurance tech, virtual care, care delivery
• Stage Focus: Series A, Series B, Series C, Growth
• Office Location: 20 University Road, Cambridge (active NYC office at 100 Fifth Avenue)
• Website: generalcatalyst.com

11. Rock Health

They run the top digital health accelerator and invest $100K-500K at pre-seed and seed.

• Recent Deals: Omada Health ($4.7M Series A, 2012), Vida Health ($3M Series A, 2015), Ginger ($3.6M Series A, 2015), One Medical ($9M Series A, 2010, IPO $245M), Carrot Fertility ($1.6M seed, 2016)
• LinkedIn: Halle Tecco
• Sector Focus: Digital therapeutics, chronic disease, behavioral health, fertility tech, preventive care
• Stage Focus: Pre-seed, Seed
• Office Location: 500 Sansome Street, San Francisco (active in NYC)
• Website: rockhealth.com

12. 8VC

They backed Oscar Health at Series A and invest $10-50M in healthcare technology and biotech.

• Recent Deals: Oscar Health ($30M Series A, 2013), Bright Health ($200M Series C, 2018), Devoted Health ($300M Series C, 2019), Alto Pharmacy ($50M Series C, 2019), Cityblock Health ($65M Series B, 2019)
• LinkedIn: Joe Lonsdale
• Sector Focus: Health insurance tech, pharmacy tech, value-based care, care delivery, healthcare infrastructure
• Stage Focus: Series A, Series B, Series C
• Office Location: 1 Letterman Drive, San Francisco (active in NYC deals)
• Website: 8vc.com

13. Human Capital

They invest exclusively in healthcare services and care delivery with $10-40M checks.

• Recent Deals: Cityblock Health ($20M Series A, 2018), SOC Telemed ($35M Series C, 2019), VillageMD ($100M Series B, 2018), Medely ($10M Series A, 2020), DispatchHealth ($33M Series B, 2019)
• LinkedIn: Alex Asch
• Sector Focus: Care delivery models, community health, telehealth, healthcare staffing, urgent care
• Stage Focus: Series A, Series B, Series C
• Office Location: 1460 Broadway, Manhattan
• Website: humancapitalvc.com

14. Health Velocity Capital

They invest $5-25M in healthcare IT infrastructure and interoperability platforms.

• Recent Deals: Commure ($12M Series A, 2019), Olive ($225M Series G, 2021), Innovaccer ($70M Series D, 2020), HealthEdge ($125M growth, 2019), nThrive ($20M Series A, 2015)
• LinkedIn: Raj Maheshwari
• Sector Focus: Healthcare infrastructure, interoperability, revenue cycle, claims processing, clinical workflows
• Stage Focus: Series A, Series B, Series C
• Office Location: 2000 West Loop South, Houston (active in NYC)
• Website: healthvelocity.com

15. Transformation Capital

They invest $15-40M in digital health and medtech at Series B and later stages.

• Recent Deals: Hinge Health ($26M Series B, 2018), Gauss Surgical ($20M Series C, 2018), HealthLoop ($17M Series B, 2017), Virta Health ($37M Series B, 2018), Cue Health ($45M Series C, 2020)
• LinkedIn: Michael Greeley
• Sector Focus: Digital therapeutics, surgical tech, chronic disease, diagnostics, remote monitoring
• Stage Focus: Series B, Series C, Growth
• Office Location: 177 Huntington Avenue, Boston (active in NYC)
• Website: transformation.vc

16. Aisling Capital

They invest $10-50M in life sciences and healthcare with biotech expertise.

• Recent Deals: Tempus ($25M Series B, 2016), Foundation Medicine ($14M Series B, 2011, sold to Roche for $2.4B), Karuna Therapeutics ($68M Series C, 2019), Mersana Therapeutics ($37M Series C, 2014), Progenics Pharmaceuticals ($25M growth, 2008)
• LinkedIn: Steve Elms
• Sector Focus: Precision medicine, oncology platforms, biotech therapeutics, clinical diagnostics, genomics
• Stage Focus: Series A, Series B, Series C, Growth
• Office Location: 888 Seventh Avenue, Manhattan
• Website: aislingcapital.com

17. ARCH Venture Partners

They invest in breakthrough biotech and medical technology with $20-100M checks.

• Recent Deals: Juno Therapeutics ($120M Series A, 2013), Denali Therapeutics ($217M Series B, 2016), Vir Biotechnology ($150M Series C, 2017), Unity Biotechnology ($116M Series B, 2016), GRAIL ($100M Series A, 2016)
• LinkedIn: Robert Nelsen
• Sector Focus: CAR-T therapy, neuroscience therapeutics, immunology, oncology, early cancer detection
• Stage Focus: Series A, Series B, Series C
• Office Location: 8755 West Higgins Road, Chicago (active in NYC)
• Website: archventure.com

18. Polaris Partners

They backed Foundation Medicine early and invest $10-40M in healthtech and life sciences.

• Recent Deals: Foundation Medicine ($14M Series B, 2011, sold to Roche for $2.4B), Concert Genetics ($20M Series B, 2014), Blueprint Medicines ($62M Series C, 2015),Vedanta Biosciences ($46M Series A, 2014), Intarcia Therapeutics ($90M Series D, 2011)
• LinkedIn: Terrance McGuire
• Sector Focus: Precision medicine, genetic testing, oncology therapeutics, microbiome, diabetes tech
• Stage Focus: Series A, Series B, Series C, Growth
• Office Location: 1000 Winter Street, Waltham (active in NYC)
• Website: polarispartners.com

Start tracking your New York healthtech investor outreach

These 18 investors closed NYC healthcare deals in 2025-2026. Before you start pitching Manhattan funds, organize your clinical data. You'll need hospital partnerships and outcomes evidence before getting meetings.

Upload your deck to Ellty and create a unique link for each New York investor. You'll see exactly which slides they review and how long they spend on your clinical validation data. NYC healthtech VCs focus heavily on patient outcomes, reimbursement strategy, and regulatory pathway. Track who's spending time on clinical results vs who's reviewing business model.

When New York investors request due diligence materials, share an Ellty data room instead of email chains. Your IRB approvals, clinical study results, hospital partnership agreements, and FDA regulatory strategy in one secure place with view analytics. You'll know which partners are conducting serious clinical review vs which ones passed after initial screening.

Common questions

Do I need to be based in New York to raise from NYC healthtech investors?

No, but expect to have New York hospital partnerships before Series A. NYC healthcare funds invest 40% locally and 60% elsewhere. Remote founders need clinical pilots at NYU Langone, Mount Sinai, or Columbia before first meetings. Location matters less than hospital relationships.

How does New York compare to Boston for healthtech fundraising?

New York has more digital health capital ($4.7B vs Boston's $3.9B in 2025) but Boston has deeper biotech expertise. Boston investors understand drug development and FDA pathways better. NYC investors know payer economics and health system operations better. Choose Boston for therapeutics or medical devices, NYC for digital health or healthcare IT.

What's the average Series A size in New York for healthtech?

$18M for digital health vs $25M for medtech. Expect 1-2 lead investors at $10-15M each, plus existing angels. Series B runs $45-70M. That's 40% higher than consumer tech because clinical validation costs more and takes longer.

Should I raise locally or go straight to NYC?

Start in New York if you're running pilots at Manhattan hospitals or selling to Northeast payers. Don't cold pitch NYC funds from Phoenix with just a prototype. Get clinical validation at 2-3 hospitals first. Then target 15-20 NYC funds plus a few Boston healthcare specialists like Polaris or Transformation Capital.

Do New York healthtech investors expect in-person meetings?

Yes for clinical diligence. First meetings can be Zoom, but clinical review meetings with their MD advisors happen in person. Budget 3-4 trips to Manhattan before closing. Expect to present to clinical advisors, not just investment partners. This is unique to healthcare.

What healthtech categories get funded most in New York?

Digital health platforms lead with 35% of deals in 2025. Healthcare IT infrastructure second at 22%. Behavioral health third at 16%. Value-based care models fourth at 14%. Diagnostics and remote monitoring fifth at 13%. Pure therapeutics rarely get funded by NYC VCs - they go to Boston biotech specialists.

How important is FDA approval for NYC healthtech investors?

Depends on your category. Software as Medical Device needs clear regulatory pathway but doesn't need approval before Series A. Clinical decision support tools that don't diagnose can avoid FDA entirely. Diagnostics need at least breakthrough device designation before Series B. Therapeutics aren't funded in NYC - go to Boston.